1. Home
  2. QNC vs CMPX Comparison

QNC vs CMPX Comparison

Compare QNC & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QNC

Quantum eMotion Corp. Common Shares

N/A

Current Price

$3.17

Market Cap

434.7M

Sector

N/A

ML Signal

N/A

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$2.06

Market Cap

371.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QNC
CMPX
Founded
2007
2014
Country
Canada
United States
Employees
5
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
434.7M
371.0M
IPO Year
2026
2020

Fundamental Metrics

Financial Performance
Metric
QNC
CMPX
Price
$3.17
$2.06
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$14.57
AVG Volume (30 Days)
1.2M
3.8M
Earning Date
04-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$934.41
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.90
$1.61
52 Week High
$3.59
$6.88

Technical Indicators

Market Signals
Indicator
QNC
CMPX
Relative Strength Index (RSI) 51.37 43.06
Support Level $2.63 $1.88
Resistance Level $3.51 $2.47
Average True Range (ATR) 0.27 0.10
MACD 0.01 0.06
Stochastic Oscillator 51.15 62.71

Price Performance

Historical Comparison
QNC
CMPX

About QNC Quantum eMotion Corp. Common Shares

Quantum eMotion Inc is dedicated to developing of a new generation of quantum-safe encryption for the quantum computing age. It is a developer of a new generation of cryptographic solutions under the acquisition of licenses. It allows clients and partners to develop secure quantum-safe encryption that can protect anything from consumer and enterprise devices like mobile phones, computers, the Internet of Things, and networking equipment to demanding cloud-based applications, servers, and military devices.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Share on Social Networks: